iBio, Inc. (IBIO)
1.695
0.00 (0.00%)
USD |
NASDAQ |
Jun 11, 15:17
iBio EPS Diluted (TTM) : -0.5777 for March 31, 2026
EPS Diluted (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical EPS Diluted (TTM) Data
| Date | Value |
|---|---|
| March 31, 2026 | -0.5777 |
| December 31, 2025 | -1.006 |
| September 30, 2025 | -1.393 |
| June 30, 2025 | -1.747 |
| March 31, 2025 | -2.335 |
| December 31, 2024 | -2.696 |
| September 30, 2024 | -6.642 |
| June 30, 2024 | -10.97 |
| March 31, 2024 | -16.01 |
| December 31, 2023 | -26.22 |
| September 30, 2023 | -90.23 |
| June 30, 2023 | -126.44 |
| March 31, 2023 | -1097.57 |
| December 31, 2022 | -1114.92 |
| September 30, 2022 | -1073.88 |
| June 30, 2022 | -1053.54 |
| March 31, 2022 | -76.36 |
| December 31, 2021 | -65.86 |
| September 30, 2021 | -60.25 |
| June 30, 2021 | -62.98 |
| March 31, 2021 | -75.95 |
| December 31, 2020 | -87.69 |
| September 30, 2020 | -409.75 |
| June 30, 2020 | -489.66 |
| March 31, 2020 | -591.26 |
| Date | Value |
|---|---|
| December 31, 2019 | -673.10 |
| September 30, 2019 | -450.58 |
| June 30, 2019 | -472.02 |
| March 31, 2019 | -527.54 |
| December 31, 2018 | -566.04 |
| September 30, 2018 | -644.74 |
| June 30, 2018 | -720.00 |
| March 31, 2018 | -800.00 |
| December 31, 2017 | -850.00 |
| September 30, 2017 | -850.00 |
| June 30, 2017 | -800.00 |
| March 31, 2017 | -700.00 |
| December 31, 2016 | -700.00 |
| September 30, 2016 | -650.00 |
| June 30, 2016 | -600.00 |
| March 31, 2016 | -550.00 |
| December 31, 2015 | -450.00 |
| September 30, 2015 | -400.00 |
| June 30, 2015 | -400.00 |
| March 31, 2015 | -387.00 |
| December 31, 2014 | -387.00 |
| September 30, 2014 | -437.00 |
| June 30, 2014 | -287.00 |
| March 31, 2014 | -333.40 |
| December 31, 2013 | -433.40 |
EPS Diluted (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (TTM) Benchmarks
| Capricor Therapeutics, Inc. | -2.313 |
| Ocugen, Inc. | -0.2318 |
| CytomX Therapeutics, Inc. | -0.3637 |
| ACADIA Pharmaceuticals, Inc. | 2.196 |
| Alnylam Pharmaceuticals, Inc. | 4.209 |